Latest news
Novel Molecular Glue Discovery Platform Unlocks Undruggable Cancer Targets - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Fri, 07 Aug 2026 17:17:14 GMTNew molecular glue platform broadens E3 ligase targeting for cancer drug development - Drug Target ReviewDrug Target Review · Fri, 07 Aug 2026 14:19:12 GMTArvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology - BitgetBitget · Fri, 07 Aug 2026 12:26:40 GMTDana-Farber team develops degrader platform, discovers first metabolically activated molecular glue - Bioengineer.orgBioengineer.org · Thu, 06 Aug 2026 21:18:49 GMTFirst metabolically activated molecular glue degrader may target cancer cells under oxidative stress - Phys.orgPhys.org · Thu, 06 Aug 2026 18:20:04 GMTJ&J inks $1B deal for Firefly Bio and its degrader-antibody platform - FirstWord PHARMAFirstWord PHARMA · Thu, 06 Aug 2026 07:00:00 GMTDCAF11-dependent molecular glue degrader activated by glutathionylation - NatureNature · Wed, 05 Aug 2026 15:30:06 GMTNurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272 - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 07:37:44 GMT